Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Complete Hematologic Response

Known as: CHR 
The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light… Expand
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
BACKGROUND Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome… Expand
  • table 1
  • table 2
  • table 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings
Abstract 210 Background: Despite progress in CML therapy, patients (pts) who fail 2 or more tyrosine kinase inhibitors (TKI), or… Expand
Is this relevant?
2010
2010
Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
To the editor: In AL amyloidosis, amyloid fibril deposits, derived from immunoglobulin light chains produced by a clonal plasma… Expand
Is this relevant?
2010
2010
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR‐ABL kinase domain mutation T315I
Resistance to tyrosine kinase inhibitor (TKIs) therapy is associated with the development of kinase domain mutations. Although… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
Although many patients with chronic myeloid leukemia (CML) respond well to imatinib therapy, a significant proportion loses their… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.
Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high… Expand
  • figure 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?
Hepatitis C virus (HCV) has been associated with the development of B-cell non-Hodgkin lymphomas. We recently reported the… Expand
  • table 1
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Simultaneous homoharringtonine and interferon‐α in the treatment of patients with chronic‐phase chronic myelogenous leukemia
Homoharringtonine (HHT) has antileukemic activity in patients with Philadelphia chromosome (Ph) positive chronic myelogenous… Expand
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy
Table. SI Units and Abbreviation Chronic myelogenous leukemia is characterized by the presence of the Philadelphia chromosome (Ph… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE